Leiden, The Netherlands, April 27, 2007- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and Novartis Vaccines and Diagnostics, Inc. today announced the extension of a non-exclusive research license agreement for PER.C6®. The license agreement allows Novartis to use Crucell's PER.C6® cell technology in manufacturing alphavirus vectors for its vaccine research programs. Financial details were not disclosed.
